ClinicalTrials.gg
RecruitingNCT04321915LEDAUpdated May 29, 2024

Intestinal Dysbiosis and BBB Integrity in Autism

An interventional study of Analysis of intestinal microbiota in autism spectrum desorder and Analysis of neuroinflammation markers in autism spectrum desorder in Autism Spectrum Disorder, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 6 Years to 16 Years. Per ClinicalTrials.gov, last updated 2024-05-29.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Apr 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
6 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Autism Spectrum Disorder by University Hospital, Montpellier — 5 open to participants now, 6 under way, none of them phase 3. Autism Spectrum Disorder · University Hospital, Montpellier.

Started
2021
the only one that year
No phase
6 of 12
2 open now
Registered
7th of 12
by date

Among the 12 studies in Autism Spectrum Disorder by University Hospital, Montpellier, this one is the only one that started in 2021, is one of 6 with no phase, and was the 7th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

5 of the 12 studies in Autism Spectrum Disorder by University Hospital, Montpellier are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 6 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Autism Spectrum Disorder by University Hospital, Montpellier, or all of them as a file.
02

Study summary

Autism Spectrum Disorder (ASD) is characterised by an impairment of social interactions and communication, associated with repetitive behaviour and restrictive interests. Clinical phenotypes of this neurodevelopmental disorder are heterogeneous and surprisingly up to 70% of ASD patients have gastro-intestinal (GI) disorders, associated with ASD severity and influence by feeding disorders.

Gut-brain axis seems to play a key role in neurodevelopment and ASD pathophysiology. Indeed an intestinal dysbiosis is observed in ASD, as well as intestinal inflammation and permeability. Aspecific inflammatory pattern suggests neuroinflammation processes in ASD. Neuroinflammation is involved in blood brain barrier (BBB) integrity and there are some arguments for a putative BBBimpairment in ASD. Nevertheless, no study has explored all together these parameters in ASD patients.

Here we hypothesise that intestinal dysbiosis in ASD could lead to a BBB impairment through neuroinflammation processes. Furthermore, this association between intestinal dysbiosis and BBB impairment could be influenced by a lot of clinical characteristics, such as ASD severity or GI disorders presence.

The principal aim of our study is to determine if the gut microbiota composition is associated with the BBB integrity in ASD. The secondary objectives are i) too identify in children with ASD some physiopathological pathways involved in this association, with a focus on associations betweenintestinal dysbiosis, intestinal permeability, intestinal permeability, the Th1/Th2 immune response, neuroinflammation and the BBB integrity; ii) to evaluate the influence of these associations on several clinical features of ASD such as ASD severity or GI disorders intensity; iii) to evaluate the influence of nutritional status on biological and clinical parameters.

This study will assess a lot of clinical and biological parameters together, some of them were never explored in ASD children. It will allow to better understand ASD pathophysiology, to highlight new therapeutic pathway, and to promote personalised medicine.

Read the detailed description

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by impaired social interactions and communication, associated with repetitive behaviors and restricted interests. The pathophysiology of ASD is complex due to clinical heterogeneity and numerous comorbidities. Surprisingly, up to 70% of children with ASD have gastrointestinal (GI) disorders, correlated with the severity of ASD. These GI disorders are influenced by eating disorders linked to ASD. There is also an imbalance of the intestinal microbiota in ASD. In addition, the gut microbiota plays a key role in regulating the gut-brain axis. It is involved in brain development and neuroinflammation, one of the pathophysiological tracks in ASD. Neuroinflammation is also involved in regulating the integrity of the blood-brain barrier (BBB), which is affected in ASD. The question if intestinal dysbiosis influences the BBB integrity in ASD therefore arises.

The main objective is to determine if there is an association between the composition of the intestinal microbiota and the integrity of the BBB in ASD.

Secondary objectives are i/ to identify the pathophysiological pathways involved in this association, in particular via the neuroinflammation processes, ii/ to estimate the influence of this association on some ASD characteristics, iii/ to determine the influence of nutritional status on the measured biological and clinical parameters.

This is a monocentric, observational and cross-sectional study of 72 children with ASD, aged 6 to 16, living in the Languedoc-Roussillon region and from the ELENA cohort (this cohort includes 900 French children with an ASD, initially aged 2 to 16, and followed for 6 years).

Serum immunoassays will be assessed for the measurement of neuroinflammation, plasma assays for the intestinal inflammation and permeability. Clinical characteristics will be collected by a clinician and parental questionnaires (ASD severity test, level of social interaction, repetitive and stereotypical behavior, behavioral disorders, quality of life, intensity of GI disorders). Nutritional status will be assessed by serum metabolome analysis and anthropomorphic measures.

Participants will be stratified according to the intensity of their ASD characteristics and the presence or absence of GI disorders.

Descriptive analyses of microbiota composition, biological markers of intestinal permeability and inflammation, neuroinflammation and BBB integrity will be performed using an Heat Map Correlation. Principal component analysis will allow to identify patterns of microbiota compositions. Associations between the different groups of measured biomarkers (microbiota patterns, BBB integrity, intestinal permeability, intestinal inflammation and neuroinflammation) will be performed using multivariate regression models. The models will be systematically adjusted for age and gender.

The study will last 4 and a half years and will end in February 2025. The inclusions will last 42 months. No specific follow-up is planned outside the 6-month maximum period between the study proposal and the inclusion visit. The study will be presented to patients at the end of their visit at 3 or 6 years of follow-up as part of the ELENA cohort. For patients meeting the inclusion criteria and who agrees to participate in the study, two visits will occur at the Center of Autism Ressources of Languedoc-Roussillon (CRA-LR), for the collection of consent and the delivery of the material to be used at home. In the week preceding their second visit to CRA-LR, parents will collect a sample of their child's stool in a dedicated jar which will be packed in a plastic bag and kept in the home-deep-freeze until they reach CRA-LR. A Bristol scale - allowing the display of the child's stools -, a PedsQL GSS questionnaire - evaluating gastrointestinal disorders - and a RBS-R questionnaire - evaluating repetitive and stereotypical behaviors - will be completed by parents. During the inclusion visit, a clinical examination of children will be performed and a blood sample will be collected.

This study will concomitantly assess many clinical and biological parameters, some of whom never explored before in children with ASD. It will allow a better understanding of the implication of the gut-brain axis in the ASD pathophysiology and will open the way to new therapeutic targets.

03

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • intestinal microbiota
  • neuroinflammation
  • brain blood barrier
  • autism spectrum disorders
04

Who can participate

Ages eligible
6 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Child from the ELENA cohort who received at least 3 years of follow-up in this cohort and a diagnosis of ASD
  • Aged 6 to 16 years
  • Living in Languedoc-Roussillon
  • Consent to participate in the study signed by the legal representative

Exclusion criteria

Exclusion criteria:

  • Syndromic autism (neuroanatomical abnormality detected on brain MRI, severe neurological syndrome or polymalformative)
  • Known severe gastrointestinal pathology (such as celiac disease or Crohn's disease)
  • Other known severe chronic disease (e.g., diabetes)
  • Specific diet (gluten-free, casein-free, ketogenic, protein-enriched) within 6 months
  • Antibiotics taken within 2 months prior to inclusion
  • Probiotics taken in the 6 months prior to inclusion
  • Oxytocin intake in the 6 months prior to inclusion
  • ADOS Level Module 4 (due to the impossibility of calculating a ADOS-CSS score in this case)
  • Not affiliated to a French social security scheme or not beneficiaries of such a scheme
  • Refusal of blood test
  • Pregnant women
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Other
    Children with Autism spectrum disorder

    Patients will realised quesstionnaires, a blood sample will be collected, the feces will be collected too. The analysis of intestinal microbiota and neuroinflammation markers will be processed.

    Other: Analysis of intestinal microbiota in autism spectrum desorder · Other: Analysis of neuroinflammation markers in autism spectrum desorder

Interventions

  • OtherAnalysis of intestinal microbiota in autism spectrum desorder

    This analysis permit to describe the diversity and composition of microbiota and the factors that may influence them. In fact, the gut microbiota plays a key role in regulating the gut-brain axis

  • OtherAnalysis of neuroinflammation markers in autism spectrum desorder

    This analysis permit to reveal the integrity of the blood-brain barrier (BBB) which is affected in autism spectrum desorder.

06

What researchers measure

Primary outcomes

  1. Intestinal microbiota assessment

    At the end of the study, the analysis will be performed on all the samples at the same time by 16S RNAr pyrosequencing.

    Time frame: 9 months

Secondary outcomes

  1. Measuring the severity of ASD

    The severity of ASD is evaluated by the ADOS2-CSS (Autism Diagnostic Observation Schedule-Calibrated Standardized Score) scale. A ADOS-CSS 4 score indicates a light TSA. It is moderate if the ADOS-CSS is between 5 and 7, and severe if it is greater than or equal to 8.

    Time frame: 24 months

  2. Evaluation of the level of social interaction

    This level is evaluated by the parental questionnaire SRS-2 (Social Responsiveness Scale-2). This scale consists of 65 items. Each item is rated from 0 (never) to 3 (almost always true).

    Time frame: 24 months

  3. Behavioural disorders

    These disorders are evaluated by the parental questionnaire ABC (Aberrant Behavior Checklist). This scale consists of 58 items. Items are rated from 0 (no problem) to 3 (severe problem).

    Time frame: 24 months

  4. Quality of life of children with ASD

    The quality of life is evaluated by the parental questionnaire Kidscreen-27. This parental questionnaire consists of 27 items. Each item is rated from 0 to 4 (not always, to very often).

    Time frame: 24 months

  5. Developmental trajectory of children with ASD

    This is evaluated by the scale Vineland II. The Vineland Scale is a 30-minute to an hour semi-structured interview administered with the child's parents. This scale is used to measure the subject's socio-adaptive abilities. Standard scores are obtained in three areas: communication, life skills and socialization. it consists of 577 items.

    Time frame: 24 months

  6. IQ (Intellectual Quotient)

    This is evaluated by psychometric tests adapted to the children.

    Time frame: 24 months

  7. Assessment of stools aspect

    This is assessed by Bristol stool scale. There is 7 types of stools to classify the consistency. The Bristol scale is a visual scale for classifying human stool according to its consistency, which depends on the time spent in the colon.

    Time frame: 24 months

  8. Repetitive and stereotypical behaviours

    These behaviors are evaluated by the parental questionnaire RBS-R (Repetitive Behavior Scale reviewed)

    Time frame: 24 months

  9. Intensity of GI disorders

    This is assessed by parental questionnaire PedsQL GSS (Gastrointestinal Symptom Scale)

    Time frame: 24 months

  10. Measurement of neuroinflammation

    Measurement of neuroinflammation by serum immunological assays of a panel of 37 neuroinflammation markers (ELISA) consisting of cytokines, chemokines, markers of inflammation, angiogenesis and vascular lesion

    Time frame: 9 months

  11. Intestinal permeability

    This is assessed by plasma assays of the following markers: zonulin and citrulline

    Time frame: 9 months

  12. Intestinal inflammation

    This is assessed by plasma assays of marker I-FABP

    Time frame: 9 months

  13. Intestinal inflammation

    This is assessed by plasma assays of marker LBP

    Time frame: 9 months

  14. Intestinal inflammation

    This is assessed by plasma assays of marker sCD14

    Time frame: 9 months

  15. TH1/TH2 immune response

    It will be done by assaying the different immune cell lines

    Time frame: 9 months

  16. Metabolome analysis

    Assessment of nutritional status by Simultaneous quantification of routinely measured lipids as well as 14 categories of lipoproteins, fatty acid composition, glycolysis precursors, ketones, and amino acids will be performed using a suitable metabolomic NMR platform.

    Time frame: 9 months

07

Study locations

1 of 1 sites recruiting
  • Centre de Ressources Autisme
    Montpellier, 34295, France
    Recruiting
    • STEPHANIE MIOT, Dr · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Dec 2024, 44 months after the start.

Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 44 months is above that.

Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2020
First posted
Mar 25, 2020
StartActual
Apr 26, 2021
Primary completionEst.
Dec 26, 2024
CompletionEst.
Feb 26, 2025
Last update
May 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04321915
Collaborators
Inserm1047, CHU Nîmes, LBPC, Inserm 1183, IRMB CHU Montpellier, UMR 5203, InsermU1191, IGF, Montpellier
Responsible party
Sponsor
First posted
Mar 25, 2020
Start date
Apr 26, 2021
Primary completion
Dec 26, 2024 (estimated)
Completion
Feb 26, 2025 (estimated)
Last update
May 29, 2024

Study contacts

Stéphanie MIOT, MD-PhD
Contact
s-miot@chu-montpellier.fr
467339687 ext. +33
Amaria BAGHDADLI, PU-PH
Contact
a-baghadadli@chu-montpellier.fr
467336383 ext. +33
Stéphanie MIOT, MD-PH
principal investigator · Montpellier University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion